Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 16, Issue 2, p.574-8 (1998)


Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Phytogenic, Disease-Free Survival, Female, Humans, Infusions, Intravenous, Lymphoma, Non-Hodgkin, Male, Middle Aged, paclitaxel, RECURRENCE, Survival Rate


The Southwest Oncology Group (SWOG) recently conducted a multiinstitutional phase II trial to determine the complete response (CR) and partial response (PR) rates, toxicities, and progression-free and overall survivals of patients with relapsed non-Hodgkin's lymphomas (NHLs) treated with a 24-hour continuous infusion of paclitaxel at a dose of 175 mg/m2.